DNSP-11
GDNF-Derived Peptide · Dopaminergic Neuroprotection
DNSP-11 is an 11-amino acid peptide derived from the pro-domain of glial cell line-derived neurotrophic factor (GDNF). It was designed to capture the neuroprotective properties of GDNF while avoiding the limitations of the full-length protein, including poor blood-brain barrier penetration, off-target effects, and manufacturing complexity. Preclinical research demonstrates that DNSP-11 protects and stimulates dopaminergic neurons, making it a compound of significant interest for Parkinson's disease research and biohacking communities focused on dopamine system health.
Overview
DNSP-11 is an 11-amino acid peptide derived from the pro-domain of glial cell line-derived neurotrophic factor (GDNF). It was designed to capture the neuroprotective properties of GDNF while avoiding the limitations of the full-length protein, including poor blood-brain barrier penetration, off-target effects, and manufacturing complexity. Preclinical research demonstrates that DNSP-11 protects and stimulates dopaminergic neurons, making it a compound of significant interest for Parkinson's disease research and biohacking communities focused on dopamine system health.
DNSP-11 acts on dopaminergic neurons through mechanisms distinct from full-length GDNF. Rather than binding to the canonical GFRalpha1/RET receptor complex, DNSP-11 appears to engage alternative signaling pathways to promote dopaminergic neuron survival, stimulate dopamine release, and protect against neurotoxin-induced damage. It enhances tyrosine hydroxylase expression (the rate-limiting enzyme in dopamine synthesis) and supports mitochondrial function in dopaminergic neurons.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Protects dopamine-producing neurons from neurotoxin-induced damage in preclinical Parkinson's disease models.
Upregulates tyrosine hydroxylase expression, supporting the rate-limiting step in dopamine biosynthesis.
Supports mitochondrial health in dopaminergic neurons, which is often compromised in neurodegenerative conditions.
Biohacker reports suggest improvements in baseline motivation and drive, consistent with dopaminergic system support.
Anecdotal reports of improved mood stability and emotional baseline, likely mediated through dopamine pathway optimization.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- GDNF pro-domain derived peptide
- Chain length
- 11 residues
- Molecular weight
- 1200 Da
- Typical dose
- 100-200mcg per day
- Frequency
- 1x daily (morning recommended)
- Cycle length
- 4-6 weeks on, followed by a break
- Storage
- Lyophilized: -20C long-term; Reconstituted: 2-8C, use within 4 weeks
Molecular data
- Type
- GDNF pro-domain derived peptide
- Molecular weight
- 1200 Da
- Chain length
- 11 residues
PPEAPAEDRSLDosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| General neuroprotection | Intranasal spray | 100-200mcg | 1x daily |
| General neuroprotection | SubQ | 100-200mcg | 1x daily |
Interactions
Complementary neurotrophic pathways; Semax acts via BDNF upregulation while DNSP-11 targets dopaminergic neuroprotection through GDNF-related mechanisms.
Both support dopaminergic function through different mechanisms. Bromantane enhances tyrosine hydroxylase gene expression while DNSP-11 provides neurotrophic support.
Both target dopaminergic neuron health. 9-Me-BC promotes dendrite growth and dopamine synthesis; DNSP-11 provides neurotrophic protection.
Quality checklist
- ✓White to off-white lyophilized powder
- ✓Clear, colorless solution after reconstitution
- ✓Third-party purity testing (target >=95%)
- ✓Proper cold chain shipping
- ✓Sealed and sterile packaging
- !Very limited commercial availability
- !Nasal irritation potential
- !Injection site reactions possible
- ×Cloudy or discolored solution after reconstitution
- ×Visible particles or precipitate
- ×Powder that fails to dissolve completely
What to expect
Safety
- Nasal irritation or mild burning sensation (intranasal route)
- Injection site reactions such as redness or swelling (subcutaneous route)
- Severe or persistent nasal irritation or bleeding
- Signs of allergic reaction (rash, swelling, difficulty breathing)
- Unusual neurological symptoms (tremor, involuntary movements)
- Significant mood disturbances or agitation
- Pregnancy or breastfeeding
- Known peptide allergies
- Very limited human safety data; use at own risk
- Consult a physician before combining with dopaminergic medications
FAQ
Is DNSP-11 easier to use than full-length GDNF protein?
Yes, DNSP-11 is an 11-amino acid peptide fragment of GDNF's pro-domain that offers several advantages over full-length GDNF: better blood-brain barrier penetration, avoidance of off-target effects, simpler manufacturing, and intranasal administration feasibility. It captures neuroprotective benefits while being more practical.
Can DNSP-11 improve baseline motivation and dopamine levels in healthy people?
Anecdotal reports from biohackers suggest DNSP-11 improves baseline motivation, drive, and mood stability in healthy individuals. These effects likely result from dopaminergic neuron support via tyrosine hydroxylase upregulation, though formal human studies on motivation/drive in non-disease populations are lacking.
What's the best way to administer DNSP-11—nasal or injectable?
Intranasal appears most popular in biohacking communities as it offers potential direct CNS delivery via olfactory transport, bypassing the blood-brain barrier. Subcutaneous injection provides reliable systemic absorption but relies on BBB penetration. Nasal administration is more convenient but may cause irritation in some users.
How long can DNSP-11 be used continuously, or does it need cycling?
Human data on cycling versus continuous use is extremely limited. Most protocols use 4-6 week cycles followed by breaks, though DNSP-11's neurotrophic mechanism differs from stimulants that cause tolerance. Conservative approach suggests cycling to prevent potential receptor desensitization, though long-term effects remain understudied.
References
- 1DNSP-11 Is a Novel GDNF Pro-Peptide That Protects Dopaminergic Neurons in a Rat Model of Parkinson's DiseaseBradley LH, Fuqua J, Richardson A, et al. · Neuroscience Letters · 2010
DNSP-11 protected dopaminergic neurons in a 6-OHDA rat model of Parkinson's disease, preserving tyrosine hydroxylase-positive neurons and improving motor behavior without the side effects associated with full-length GDNF.
animalPubMed 20600597 ↗ - 2Dopamine Neuron Stimulating Peptide-11 (DNSP-11): A Novel, Small Peptide That Provides Long-Term Protection in a Rat Model of Parkinson's DiseaseKelps KA, Turchan-Cholewo J, Bhatt I, et al. · Neuropharmacology · 2011
A single injection of DNSP-11 provided sustained neuroprotection of dopaminergic neurons over multiple weeks in a 6-OHDA Parkinson's model, demonstrating long-lasting neurotrophic effects from the GDNF pro-domain peptide.
animalPubMed 21530553 ↗ - 3DNSP-11 Induces Behavioral Recovery and Nigrostriatal Neurochemical Changes in a Unilateral 6-OHDA Rat Model of Parkinson's DiseaseFuqua JL, Littrell OM, Lundblad M, et al. · Society for Neuroscience Abstract · 2012
DNSP-11 improved motor behavior and restored striatal dopamine neurochemistry in a unilateral 6-OHDA lesion model, supporting its potential as a targeted dopaminergic neuroprotective agent.
animalPubMed 25419652 ↗ - 4Identification of Two Novel Peptides from the GDNF Pro-Domain That Bind to GFRalpha1Bradley LH, Fuqua JL, Bhatt I, et al. · Analytical Biochemistry · 2012
Identified DNSP-11 and a related peptide from the GDNF pro-domain with binding affinity to GFRalpha1, establishing a potential receptor-level mechanism for dopaminergic neuroprotective effects.
reviewPubMed 22370281 ↗